Lyell Immunopharma, Inc. (LYEL)

Market Cap	492.48M +137.1%
Revenue (ttm)	36,000 -41.0%
Net Income	-274.45M
EPS	-16.06
Shares Out	23.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	173,389
Open	21.37
Previous Close	21.25
Day's Range	20.53 - 22.64
52-Week Range	7.65 - 45.00
Beta	-0.15
Analysts	Strong Buy
Price Target	27.25 (+28.96%)
Earnings Date	Mar 12, 2026

About LYEL

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi‑R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 17, 2021
• Employees: 300
• Stock Exchange: NASDAQ
• Ticker Symbol: LYEL
• Website: https://www.lyell.com

Financial Performance

In 2025, Lyell Immunopharma's revenue was $36,000, a decrease of -40.98% compared to the previous year's $61,000. Losses were -$274.45 million, -19.98% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for LYEL stock is "Strong Buy." The 12-month stock price target is $27.25, which is an increase of 28.96% from the latest price.

Price Target

$27.25

(28.96% upside)

Analyst Consensus: Strong Buy